

fentaNYL 2,500 mcg/250 mL D5W or 0.9% NaCl

SUPPLIES

include quantity and medication name, strength/concentration, volume, diluent, diluent volume, and quantity and name of each supply needed

*****NS flush syringes are never to be used for reconstitution/diluent for medication.*****

- One (1) fentaNYL injection 50 mcg/mL vial 50 mL
- One (1) dextrose 5% in water (D5W) or 0.9% NaCl 250 mL
- Alcohol swabs
- Two (2) 18 gauge needles preferred (20-23 gauge needles acceptable)
- Two (2) 50 mL sterile IV syringes
- Nursing IV admixture label(s) – Lawson # 626

STEPS

explicitly state each step in chronological order, including hand washing, gown/garb, alcohol swab, etc.)

1. Wash hands. Prepare/clean the designated mixing area.
2. Flip the cap off of the fentaNYL 50 mg/mL injection vial, wipe the rubber stopper with alcohol swab, and wipe the injection port of the ordered diluent bag (D5W/0.9% NaCl).
3. Attach 18 gauge needle to syringe. Withdraw 50 mL from ordered diluent bag and discard syringe with needle into a sharp container.
4. Attach 18 gauge needle to another syringe. Withdraw 50 mL of fentaNYL 50 mcg/mL injection.
5. Transfer 50 mL of fentaNYL 50 mcg/mL injection into the ordered diluent bag, and discard syringe with needle into a sharp container.
6. Gently invert bag to mix. Do not shake. Visually inspect solution (e.g. free of inappropriate visible particulates or other foreign matter, discoloration, and defect), and the container integrity is intact. Discard if any defects.
7. Label the fentaNYL 2,500 mcg/250 mL infusion bag with:
 - a. Drug name, strength, and dose (if not apparent by the container)
 - b. Diluent and volume (if not apparent by the container)
 - c. Hang-by date and time (**Administration must begin within 1 hour from the time of compounding**)
 - d. Initials of person compounding

NOTES

explicitly state (if applicable) any pertinent information

- Protect final product from light. Cover with light protected plastic bag (e.g. brown plastic bag).

References

- fentaNYL injection [prescribing information]. Lake Forest, IL: Hospira, Inc. Revised: 12/2023.
<https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1ed25b2c-334e-4021-ada1-3396f07630dc&type=display>.
- United States Pharmacopeia (USP). General Chapter, <797> Pharmaceutical Compounding—Sterile Preparations. (2023) USP-NF. Rockville, MD: United States Pharmacopeia.
<https://ochsnerhealth.sharepoint.com/sites/ClinicalResources/SiteAssets/Forms/AllItems.aspx?id=%2Fsites%2FClinicalResources%2FSiteAssets%2FSitePages%2FRegulatory%2DReadiness%2FUSP%2D797%2DOfficial%2D11%2E1%2E23%2Epdf&parent=%2Fsites%2FClinicalResources%2FSiteAssets%2FSitePages%2FRegulatory%2DReadiness>.